Compare CLST & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | ALXO |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.8M | 68.3M |
| IPO Year | 2021 | 2020 |
| Metric | CLST | ALXO |
|---|---|---|
| Price | $16.73 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.42 |
| AVG Volume (30 Days) | 3.8K | ★ 1.0M |
| Earning Date | 04-30-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.02 |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.67 | $0.41 |
| 52 Week High | $16.98 | $2.66 |
| Indicator | CLST | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 68.57 | 52.41 |
| Support Level | $12.12 | $1.41 |
| Resistance Level | N/A | $2.27 |
| Average True Range (ATR) | 0.29 | 0.27 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 81.75 | 23.08 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.